Pharmacokinetic Study of Adjuvant Capecitabine After Resection of Pancreatic Adenocarcinoma

Phase 4 Completed 13 enrolled Cambridge University Hospitals NHS Foundation Trust

NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to evaluate the pharmacokinetics (PK) of adjuvant capecitabine in patients who have undergone proximal pancreatico-duodenectomy.

Timeline

Start: 2009-11
Primary completion: 2012-08
Completion: 2012-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Capecitabine	Small molecule	1250 mg/m2	Oral

Pharmacokinetic Study of Adjuvant Capecitabine After Resection of Pancreatic Adenocarcinoma

Summary

Timeline

Drugs

Indications